Annie-Laurie McRee1, Mira L Katz2, Electra D Paskett2, Paul L Reiter2. 1. College of Public Health, The Ohio State University, 1841 Neil Avenue, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Electronic address: almcree@cph.osu.edu. 2. College of Public Health, The Ohio State University, 1841 Neil Avenue, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Abstract
BACKGROUND: Human papillomavirus (HPV) infection and associated cervical disease are common among all women, regardless of sexual identity, yet limited research has examined HPV vaccination among lesbian and bisexual women. METHODS: A national sample of lesbian and bisexual women ages 18-26 (n=543) completed our online survey during Fall 2013. We used multivariable logistic regression to identify correlates of HPV vaccine initiation (receipt of at least 1 dose) and completion (receipt of all 3 recommended doses among initiators). RESULTS: Overall, 45% of respondents had initiated HPV vaccine and 70% of initiators reported completing the series. HPV vaccine initiation was higher among respondents who were students, had received a healthcare provider's recommendation, perceived greater positive social vaccination norms, or anticipated greater regret if they did not get vaccinated and later got HPV. Initiation was lower among those who perceived greater HPV vaccine harms or greater barriers to getting the vaccine (all p<.05). HPV vaccine completion was higher among initiators who had a college degree while it was lower among those who perceived a greater likelihood of acquiring HPV or who anticipated greater regret if they got the vaccine and fainted (all p<.05). Among HPV vaccine initiators who had not yet completed the series, about half (47%) intended to get the remaining doses. CONCLUSIONS: Many lesbian and bisexual women are not getting vaccinated against HPV. Healthcare provider recommendations and women's health beliefs may be important leverage points for increasing vaccination among this population.
BACKGROUND:Humanpapillomavirus (HPV) infection and associated cervical disease are common among all women, regardless of sexual identity, yet limited research has examined HPV vaccination among lesbian and bisexual women. METHODS: A national sample of lesbian and bisexual women ages 18-26 (n=543) completed our online survey during Fall 2013. We used multivariable logistic regression to identify correlates of HPV vaccine initiation (receipt of at least 1 dose) and completion (receipt of all 3 recommended doses among initiators). RESULTS: Overall, 45% of respondents had initiated HPV vaccine and 70% of initiators reported completing the series. HPV vaccine initiation was higher among respondents who were students, had received a healthcare provider's recommendation, perceived greater positive social vaccination norms, or anticipated greater regret if they did not get vaccinated and later got HPV. Initiation was lower among those who perceived greater HPV vaccine harms or greater barriers to getting the vaccine (all p<.05). HPV vaccine completion was higher among initiators who had a college degree while it was lower among those who perceived a greater likelihood of acquiring HPV or who anticipated greater regret if they got the vaccine and fainted (all p<.05). Among HPV vaccine initiators who had not yet completed the series, about half (47%) intended to get the remaining doses. CONCLUSIONS: Many lesbian and bisexual women are not getting vaccinated against HPV. Healthcare provider recommendations and women's health beliefs may be important leverage points for increasing vaccination among this population.
Authors: M Jane Park; Tina Paul Mulye; Sally H Adams; Claire D Brindis; Charles E Irwin Journal: J Adolesc Health Date: 2006-07-10 Impact factor: 5.012
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky Journal: Am J Epidemiol Date: 2003-02-01 Impact factor: 4.897
Authors: J M Marrazzo; L A Koutsky; K L Stine; J M Kuypers; T A Grubert; D A Galloway; N B Kiviat; H H Handsfield Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath Journal: CA Cancer J Clin Date: 2015-07-17 Impact factor: 508.702
Authors: Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Julia López; Vy T Pham; Betelihem B Tobo; Leping Wan; Mario Schootman; Jane A McElroy Journal: Hum Vaccin Immunother Date: 2020-07-23 Impact factor: 3.452
Authors: Shannon M Christy; Joseph G Winger; Elizabeth W Raffanello; Leslie F Halpern; Sharon Danoff-Burg; Catherine E Mosher Journal: J Behav Med Date: 2016-01-18
Authors: Madina Agénor; Sarah Peitzmeier; Allegra R Gordon; Sebastien Haneuse; Jennifer E Potter; S Bryn Austin Journal: Ann Intern Med Date: 2015-07-21 Impact factor: 25.391
Authors: Madina Agénor; Sarah M Peitzmeier; Allegra R Gordon; Brittany M Charlton; Sebastien Haneuse; Jennifer Potter; S Bryn Austin Journal: Cancer Causes Control Date: 2016-08-09 Impact factor: 2.506